Inclusion Criteria:

   1. All consenting adults who are 18 to 60 years, living donor transplant candidates and
   have a haplotype related living donor or > 2 HLA antigen matched, unrelated, living
   donor (including at least one HLA-DR antigen match plus at least one antigen match of
   either HLA-A or HLA-B).

   2. Patients who agree to participate in the study and sign an Informed Consent.

   3. Patients who have no known contraindication to administration of rabbit ATG or
   radiation.

   4. Males and females of reproductive potential who agree to practice a reliable form of
   contraception for at least 24 months post-transplant.

   5. ABO compatible.

Exclusion Criteria:

   1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins.

   2. History of malignancy with the exception of non-melanoma skin malignancies.

   3. Pregnant women or nursing mothers.

   4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection.

   5. Seronegative for Epstein-Barr virus, if donor is seropositive.

   6. Leukopenia (with a white blood cell count < 3000/mm3) or thrombocytopenia (with a
   platelet count < 100,000/mm3).

   7. Panel Reactive Antibody greater than 80% or demonstration of donor specific antibody
   (DSA).

   8. Prior organ transplantation.

   9. High risk of primary kidney disease recurrence (e.g atypical HUS). However, patients
   with primary FSGS will not be excluded.